Achillion Announces Upcoming Scientific Presentations at the 55th ERA-EDTA Congress
May 11 2018 - 6:05AM
- Oral presentation discussing ACH-4471 and
interim biomarker data from the ongoing 14-day Phase 2 study in C3G
-
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a
biopharmaceutical company focused on advancing oral small-molecule
factor D inhibitors to modulate the complement alternative pathway
for orphan diseases, today announced that two abstracts were
accepted for presentation at the 55th European Renal
Association-European Dialysis and Transplant Association (ERA-EDTA)
Congress being hosted in Copenhagen, Denmark from May 24 – 27,
2018.
Abstracts can be accessed on the ERA-EDTA
website at http://www.era-edta2018.org/en-US/home.Reprints of the
oral and poster presentations will be available following their
presentation under the resources section of the Achillion website
at http://www.achillion.com.
Poster PresentationTitle: Complement-mediated
bactericidal activity against Escherichia coli and Neisseria
MeningitidisPoster #: FP082Date/Time: 9:30a – 5:00pm CET, Friday,
May 25, 2018
Oral PresentationTitle: Factor D inhibition with
ACH-4471 to reduce complement alternative pathway hyperactivity and
proteinuria in C3 GlomerulopathySession: Glomerulonephritis
1Date/Time: 11:45a CET, Saturday, May 26, 2018
About the Complement Factor D
Platform
Achillion has leveraged its internal discovery
capabilities and a novel complement-related drug development
platform to develop small molecule factor D inhibitor compounds
that target the complement Alternative Pathway (AP). Factor D is an
essential serine protease involved in the AP, a part of the innate
immune system. Achillion's complement platform is focused on
seeking to advance small molecule compounds that inhibit factor D
and can potentially be used in the treatment of immune-related
diseases in which the AP plays a critical role. Potential
indications currently being evaluated for these compounds include
C3G, immune complex-mediated membranoproliferative
glomerulonephritis (IC-MPGN), and paroxysmal nocturnal
hemoglobinuria (PNH).
About C3G
C3G is a devastating disease affecting the
kidneys for which there is no FDA approved therapy. C3G affects men
and women equally. There are estimated to be approximately 4,000
C3G patients in the United States, more than 4,000 in Europe, and
more than 1,000 patients with this disease in Japan. C3G is a rare
renal disease characterized by the presence of predominantly C3
protein fragments in the filtering units (glomeruli) of the kidney.
These C3 fragment deposits are thought by experts to be the result
of overactivation of the complement alternative pathway (AP). The
chronic deposition of C3 fragments results in inflammation in the
glomeruli (glomerulonephritis) and subsequent permanent renal
damage. An estimated 30-50% of C3G patients will require dialysis
or a transplant within 10 years of diagnosis.
About Achillion
Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is
a science-driven, patient-focused company seeking to leverage its
capabilities across the continuum from discovery to
commercialization in its goal of providing better treatments for
people with serious diseases. The company employs a
highly-disciplined discovery and development approach that has
allowed it to build a platform of potent and specific complement
factor D inhibitors for AP-mediated diseases. Achillion is rapidly
advancing its efforts to become a fully-integrated pharmaceutical
company with a goal of bringing life-saving medicines to patients
with rare diseases. More information is available
at http://www.achillion.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that are subject to risks, uncertainties and
other important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements.
Achillion may use words such as “expect,” “anticipate,” “project,”
“target,” “intend,” “plan,” “aim,” “believe,” “seek,” “estimate,”
“can,” “could” “focus,” “will,” “look forward,” “goal,” and “may”
and similar expressions to identify such forward-looking
statements. These forward-looking statements also include
statements about: Achillion’s expected plans, timing, data readouts
and results from ongoing and planned clinical trials of ACH-4471;
the potential advancement of Achillion’s other small molecule
factor D inhibitors; the anticipated costs and benefits of
Achillion’s restructuring plans; Achillion’s expectations regarding
the CEO transition; and other statements concerning Achillion’s
strategic goals, milestone plans, and prospects. Among the
important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
are risks relating to, among other things Achillion’s ability to:
advance the preclinical and clinical development of its complement
factor D inhibitors under the timelines it projects in current and
future preclinical studies and clinical trials; realize the planned
cost savings benefits of its restructuring plan; obtain and
maintain patent protection for its drug candidates and the freedom
to operate under third party intellectual property; demonstrate in
any current and future clinical trials the requisite safety,
efficacy and combinability of its drug candidates; obtain and
maintain necessary regulatory approvals; establish commercial
manufacturing arrangements; identify and enter into collaboration
agreements with third-parties; compete successfully in the markets
in which it seeks to develop and commercialize its product
candidates and future products; manage expenses and achieve the
levels of research and development expense, cash burn, and net loss
it has projected for fiscal 2018; manage litigation; raise the
substantial additional capital needed to achieve its business
objectives; and successfully execute on its business strategies.
These and other risks are described in the reports filed by
Achillion with the U.S. Securities and Exchange Commission,
including its Annual Report on Form 10-Q for the quarter ended
March 31, 2018, and any subsequent SEC filings.
In addition, any forward-looking statement in
this press release represents Achillion's views only as of the date
of this press release and should not be relied upon as representing
its views as of any subsequent date. Achillion disclaims any duty
to update any forward-looking statement, except as required by
applicable law.
Investors & Media:
Glenn Schulman, PharmD, MPH
Executive Director, Investor Relations
Achillion Pharmaceuticals, Inc.
Tel. (203) 752-5510
gschulman@achillion.com
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Sep 2023 to Sep 2024